Seed and early stage investments in exceptional technology and life sciences companies.


Redalpine news

AstraZeneca to collaborate with Biognosys on large proteome quantification (24/11/2014)
Biognosys (RAC I), the leading proteomics company offering services and products for highly multiplexed protein quantification, just announced a collaboration with AstraZeneca, who will use Biognosys’ recently launched Proteome – SEQ™ service. This is another addition to a growing list of leading pharmaceutical companies using the next-generation proteomics technology of Biognosys. Proteome-SEQ™ is a comprehensive [...] More.

Portfolio Update: InSphero, MedMira and the Rebranding of Ebuzzing (09/10/2014)
We have witnessed an exciting start into the last quarter of the year with a lot of activity across our portfolio companies. Here are some highlights to keep you up-to-date: After taking top spot in the Swiss TOP 100 Startup Awards last month, InSphero (RAC I) has now won also the pan-European ACES award for [...] More.

Redalpine invests in Knip – Switzerland’s first fully digital insurance broker (06/10/2014)
Redalpine welcomes another truly disruptive company to its Capital II portfolio. Knip, Switzerland’s first fully digital insurance broker, offers an unrivalled user experience: Insurance policies overview and management combined with smart analysis to optimise your insurance portfolio and easy claims notifications – all conveniently packaged into a smartphone app. Insurance app Knip secures Series A [...] More.

More More Redalpine news

Industry news

What investors say

"The idea of Redalpine is bridging a gap in the market. The experienced team stands for future successes."
Fritz Fahrni, Professor for Technology Management and Entrepreneurship at HSG and ETH Zurich
"To evaluate the potential of a new idea requires experience and a clear understanding of the products and market dynamics. We trust in the team of Redalpine to master this challenge successfully."
Jürg Staub, General Partner, Reichmuth & Co, Privatbankiers

More More investor quotes

Connect with us

Subscribe to our news

Find us on Facebook

Find us on Twitter

Find us on LinkedIn